uniQure N.V. (NASDAQ:QURE) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

uniQure N.V. (NASDAQ:QURE) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

We issued a press release on March 15, 2017 announcing uniQure N.V.’s (the “Company’s”) financial results for the full year ended December 31, 2016 and providing an update on the Company’s progress. A copy of this press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report on Form 8-K, including the Exhibit attached hereto, is being furnished under Item 2.02 and shall not be deemed ‘‘filed’’ for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated March 15, 2017, relating to the Company’s financial results for the full year ended December 31, 2016 (furnished only).


About uniQure N.V. (NASDAQ:QURE)

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson’s Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington’s disease, in which the Company has demonstrated preclinical proof of concept.

uniQure N.V. (NASDAQ:QURE) Recent Trading Information

uniQure N.V. (NASDAQ:QURE) closed its last trading session down -0.12 at 6.10 with 58,644 shares trading hands.